LA JOLLA, Calif., September 16, 2008 — Burnham Institute for Medical Research today announced that Stuart A. Lipton, M.D., Ph.D., professor and director of the Del E. Webb Neuroscience, Aging, and Stem Cell Research Center at Burnham has been awarded $8 million, over five years, to establish a Center for Neurodegeneration Science (CNS). The center will study potential environmental causes of Parkinsons disease. Funding for the center comes from the National Institute of Environmental Health Sciences (NIEHS) of the National Institutes of Health.
LA JOLLA, Calif., Oct. 2, 2008 — The Salk Institute for Biological Studies and Burnham Institute for Medical Research today announced the identification of 295 host cell factors that are involved in human immunodeficiency virus (HIV) infection. The study, published in the Oct. 3 issue of Cell, could lead to the development of a new class of HIV therapeutics aimed at disrupting the human-HIV interactions that lead to viral infection.
LA JOLLA, Calif., October 7, 2008 — Burnham Institute for Medical Research today announced that scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer. The research, which was published as the featured article in the October 7 edition of Cancer Cell, may lead to new cancer treatments.
LA JOLLA, Calif., October 13, 2008 — Burnham Institute for Medical Research today announced that five of the Institutes postdoctoral research associates will be honored with Fishman Fund Awards to recognize their commitment to basic biomedical research. The awardees will receive $5,000 grants to be used to further their education and career development.
LA JOLLA, Calif., December 1, 2008Researchers at the Burnham Institute for Medical Research have shown in both fruit flies and humans that genes involved in embryonic heart development are also integral to adult heart function. The study, led by Rolf Bodmer, Ph.D., was published in Proceedings of National Academy of Sciences.
The National Institute of Allergy and Infectious Diseases estimates that up to 45 percent of deaths in the developed world involve chronic fibrotic processes. Under a patent license from the Burnham Institute for Medical Research (Burnham) in which Burnham researcher Dr. Erkki Ruoslahti is a named inventor, Genzyme Corporation is conducting clinical trials on GC-1008, an anti-fibrotic drug.
Contact: Cindy Fox Aisen firstname.lastname@example.org 317-274-7722 Indiana University School of Medicine Discovery may lead to new treatments for late-stage cancers INDIANAPOLIS – Researchers from the Indiana University School of Medicine and colleagues at the University of Texas Southwestern and Case Western University have …
Contact: Robert Nellis email@example.com 507-284-5005 Mayo Clinic Animal study demonstrates how whole chromosome changes cause cancer ROCHESTER, Minn. — Mayo Clinic researchers have proven the longstanding theory that changes in the number of whole chromosomes — called aneuploidy — can cause cancer by eli…